C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases

Medical Hypotheses

Volumn 62, Issue 4, 2004, Pages 499-506

  Li, Jian Jun ^a,b   Fang, Chun Hong ^a  

^a WUHAN UNIVERSITY   (China)

^b Tsinghua University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPID; SIMVASTATIN; STATINE;

ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CORONARY ARTERY OBSTRUCTION; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; LEUKOCYTE; LIFESTYLE; LIPID BLOOD LEVEL; MONOCYTE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING CESSATION; UNSTABLE ANGINA PECTORIS; VASCULAR ENDOTHELIUM; WEIGHT REDUCTION;

ANGINA;

EID: 1842505521     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2003.12.014     Document Type: Article

References (56)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26.
2. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001;103:1718-20.
3. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001;89:763-71.
4. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813-8.
5. Ferranti SD, Rifai N. C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. Clin Chim Acta 2002;317:1-15.
6. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel amd promising marker of coronary heart disease. Clin Chem 2001;47:403-11.
7. Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of the pneumococcus. J Exp Med 1930;52:561-71.
8. MacLeod CM, Avery OT. The occurrence during acute infections of a protein not normally present in blood. II. Isolation and properties of the C-reactive protein. J Exp Med 1941;73:183.
9. Clyne B, Olshaker JS. The C-reactive protein. J Emerg Med 1999;17:1019-25.
10. Kolb-Bachofen V. A review on the biological properties of C-reactive protein. Immunobiology 1991;183:133-45.
11. Ballou SP, Kushner I. C-reactive protein and the acute phase response. Adv Int Med 1992;37:313-36.
12. Young B, Gleeson M, Cripps AW. C-reactive protein: a critical review. Pathology 1991;23:118-24.
13. Meier-Ewert HK, Ridker PM, Rifai N, Price N, Dinges DF, Mullington JM. Absence of diurnal variation of C-reactive protein levels in healthy human subjects. Clin Chem 2001;47:426-30.
14. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001;47:444-50.
15. Powell LJ. C-reactive protein-a review. Am J Med Tech 1979;45:138-48.
16. Jaye DL, Waites KB. Clinical applications of C-reactive protein in pediatrics. Pediatr Infect Dis J 1997;16:735-47.
17. de Beer FC, Hind CPK, Fox KM, Allan RM, Maseri A, Pepys MB. Measurement of serum C-reactive protein concentration in myocardial ischemia and infarction. Br Heart J 1982;47:239-43.
18. Pietila K, Harmoinen A, Poyhonen L, Koskinen M, Heikkila J, Ruosteenoja R. Intravenous strptokinase treatment and serum C-reactive protein in patients with acute myocardial infarction. Br heart J 1987;58:225-9.
19. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331:417-24.
20. Li J-J, Jiang H, Huang CX, Fang CH, Tang Q-Z, Xia H, et al. Elevated levels of plasma C-reactive protein in patients with unstable angina: its relations with coronary stenosis and lipid profile. Angiology 2002;53:265-72.
21. Li J-J, Li G-S, Fang C-H, Chen M-Z, Chen X, Jiang H, Huang C-X, Tang Q-Z. Activation of nuclear factor-κB and correlation with elevated plasma C-reactive protein in patients with unstable angina. Heat lung and Circulation 2003; in press.
22. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, et al. C-reactive protein is a potent predictor of mortality independently of and in combination troponin T in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol 1998;31:1460-5.
23. de Winter RJ, Bholasingh R, Lijmer JG, Koster RW, Gorgels JP, Schouten Y. Independent prognostic value of C-reactive protein and troponin I in patients with unstable angina or non-Q-wave myocardial infarction. Cardiovasc Res 1999;42:240-5.
24. Liuzzo G, Biasucci LM, Rebuzzi AG, Gallimore JR, Caligiuri G, Lanza GA, et al. Plasma protein acute-phase response in unstable anigina is not induced by ischemic injury. Circulation 1996;94:2373-80.
25. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
26. Ridker PM, Hennekens CH, Buring JE, Rafai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-43.
27. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple risk factor intervention trial. Am J Epidemiol 1996;144:537-47.
28. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction [see comments]. Circulation 1998;97:2007-11.
29. Rowe IF, Walker LN, Bowyer DE, Soutar AK, Smith LC, Bepys MB. Immunohistochemical studies of C-reactive protein and apolopoprotein B in inflammatory and arterial lesions. J Pathol 1985;145:241-9.
30. Reynold GD, Vance RP. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch Pathol Lab Med 1987;111:265-9.
31. Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000;20:2094-9.
32. Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Waltenberger J, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998;18:1386-92.
33. Du Clos TW. Function of C-reactive protein. Ann Med 2000;32:274-8.
34. Bharadwaj D, Stein MP, Volzer M, Mold C, Du Clos TW. The major receptor for C-reactive protein on leukocytes is Fcγ receptor II. J Exp Med 1999;190:585-90.
35. Li J-J, Chen X-J. Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein as well as lipopolysaccharide. Coron Artery Dis 2003;14: 329-34.
36. Pascrei V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-8.
37. Pasceri V, Chang J, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531-4.
38. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001;103: 1194-7.
39. Tracy R. Inflammation in cardiovascular disease: cart, house or both? Circulation 1998;97:2000-2.
40. Ballou SP, Cleveland RP. Binding of human C-reactive protein to monocytes: analysis by flow cytometry. Clin Exp Immunol 1991;84:329-35.
41. Lauten WB, Khan QA, Rajagopalan S, Lerakins, Rahman ST, Parthasarathy S, et al. Usefulness of quinapril and irbesartan to improve the anti-inflammatory response of atorvastatin and aspirin in patients with coronary heart disease. Am J Cardiol 2003;91:1116-9.
42. Anzai T, Yoshikawa T, Takahashi T, Maekawa Y, Okabe T, Asakura Y, et al. Early use of beta-blockers is associated with attenuation of serum-Creactive protein elevation and favorable short-term prognosis after acute myocardial infarction. Cardiology 2003;99:47-53.
43. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka U, Suresh R, et al. Effect of Ezetimibe coadministration with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circualtion 2003;28.
44. Cha JK, Jeong MH, Lee KM, Bae HR, Lim YJ, Park KW, et al. Changes in platelet p-selectin and in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. J Thromb Thrombolysis 2002;14:145-50.
45. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003;289:1799-804.
46. de Maat MP, Kluft C. The association between inflammation markers, coronary artery disease and smoking. Vasc Pharmacol 2002;39:137-9.
47. Ikonomidas I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999;100:793-8.
48. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events (CARE) Investigators. Circulation 1998;98:839-84.
49. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air force/Texas coronary atherosclerosis prevention study. JAMA 1998;279:1615-22.
50. Li J-J, Chen M-Z, Chen X, Fang C-H. Rapid effects of simvastatin on lipid profile and C-reactive protein in patients with hypercholesterolemia. Clin Cardiol 2003; 26:472-6.
51. Li J-J. Effect of a single high-does simvastatin on C-reactive protein in patients with unstable angina. Cardiology; in press.
52. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001;103: 1191-3.
53. Tchermof A, Nolan A, Sites CK, Ades PA, Poehlman ET. Weight loss reduced C-reactive protein levels in obsess postmenopausal women. Circulation 2002;105:564-9.
54. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999;100: 713-6.
55. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the post-menopausal estrogen/progestin interventions (PEPI) study. Circulation 1999;100:717-22.
56. Li J-J. Silent myocardial ischemia may be related to inflammatory response. Med Hypotheses 2004; in press.